Prof. Nazik Hammad, the Chief Medical Officer for Oncology at Bio Usawa.

Kigali, Rwanda and San Francisco, USA – 10 May 2026 — Bio Usawa is honored to welcome Prof. Nazik Hammad as Chief Medical Officer for Oncology, bringing decades of global leadership at the intersection of clinical medicine, academic excellence, and cancer care equity.

Prof. Hammad joins Bio Usawa while on sabbatical from an accomplished academic career and ongoing leadership roles as a Professor of medical oncology at the University of Toronto, Canada, and a senior leader within AORTIC (African Organisation for Research and Training in Cancer). During this sabbatical period, she will be based in Rwanda and will lead Bio Usawa’s overall oncology clinical development strategy, guiding the scientific and clinical vision as the company advances high-quality, accessible cancer therapies for Africa and beyond.

With a career spanning clinical practice, academic research, and global oncology leadership, Prof. Hammad has been deeply involved in the application of monoclonal antibodies across multiple therapeutic areas. Over decades, this work has included witnessing firsthand the profound, life-changing impact these therapies can have for patients. That experience now informs a clear and compelling mission: ensuring that monoclonal antibodies of the same global quality standards become affordable and accessible to patients across Africa.

Prior to this appointment, Prof. Hammad served as a member of Bio Usawa’s Scientific Advisory Board, contributing strategic insight to the company’s oncology pipeline and long-term vision. In the role of CMO for Oncology, her leadership will focus on shaping clinical development plans, aligning medical strategy with global regulatory expectations, and ensuring patient-centered, ethically grounded innovation across Bio Usawa’s oncology portfolio.

“It is an honor to step into this role at such a pivotal moment for Bio Usawa,” said Prof. Hammad. “The opportunity to help advance equitable access to life-saving therapies across Africa is deeply meaningful. I look forward to working alongside a talented and mission-driven team to deliver high-quality, patient-centered innovation.”

Dr. Menghis Bairu, the CEO and President of Bio Usawa, welcomed the appointment, noting Prof. Hammad’s unique blend of clinical excellence, academic leadership, and commitment to health equity.

“Prof. Nazik Hammad has already demonstrated exceptional leadership and insight as a member of our Scientific Advisory Board. Her vast expertise in oncology, combined with her passion for advancing equitable care, makes her the ideal leader to guide our oncology strategy. We are excited to have her join the executive team as we continue building a biopharmaceutical company rooted in Africa and committed to global impact.”

Prof. Hammad’s work is driven by the belief that scientific excellence and health equity are inseparable. Through this role, Bio Usawa continues to strengthen its commitment to building world-class biologics programs rooted in Africa, designed to deliver meaningful impact for patients who have historically been left behind.

About Bio Usawa Inc.

Bio Usawa Biotechnology is a global health innovation company dedicated to advancing equitable access to biologic medicines through modular manufacturing technologies. By enabling nations to produce their own monoclonal antibodies and other advanced therapies, Bio Usawa is helping build resilient, sustainable, and locally empowered biopharmaceutical ecosystems. For more information, visit www.biousawa.com.